Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Lu, P; Wang, SC; Franzen, CA; Venkataraman, G; McClure, R; Li, L; Wu, WJ; Niu, NF; Sukhanova, M; Pei, JM; Baldwin, DA; Nejati, R; Wasik, MA; Khan, N; Tu, YF; Gao, JH; Chen, YH; Ma, S; Larson, RA; Wang, YL

Wang, YL (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.; Wang, YL (corresponding author), Univ Chicago Med, Chicago, IL 60637 USA.

BLOOD CANCER JOURNAL, 2021; 11 (2):

Abstract

Ibrutinib inhibits Bruton tyrosine kinase while venetoclax is a specific inhibitor of the anti-apoptotic protein BCL2. Both drugs are highly effective......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索